Boehringer Targets Hearing Loss In First China Pharma R&D collaboration
Joining a growing number of its multinational peers tapping into China’s expanding innovative capabilities, Boehringer Ingelheim has teamed up with an academic research group to develop novel stem cell therapies for hearing loss, further encouraged by new state support for regenerative medicine.
You may also be interested in...
Hanmi shares have gone on a wild roller coaster ride as bad news came after good. A day after it announced a huge licensing agreement with Genentech, the South Korean firm unveiled that Boehringer Ingelheim had decided to return rights to olmutinib, the EGFR inhibitor it licensed from Hanmi last July.
Continuing with a double-digit growth rate, China remained a leading driver for Sanofi’s global business in the fourth quarter. Going digital and building local partnerships emerged as key themes for Sanofi China to explore more opportunities, although it may face testing problems for its vaccine business in the country.
Oncologie acquires PS-targeting candidate bavituximab, which may help other cancer therapies in attacking tumors. BridgeBio's newest spinout will develop former Novartis cancer candidate infigratinib.